This may mean pausing treatment, switching to a lower-dose formulation, exploring alternative peptides, or reconsidering the medication class altogether
At 40mg/mL, GHK-Cu makes up 62.5% of every microliter, and the three repair/anti-inflammatory peptides each contribute 12.5%
GLP-1 medications work on brain reward pathways and appetite centres, potentially reducing food cravings and loss-of-control eating beyond simple hunger suppression
By 48 weeks, significant average weight loss was seen at all maintenance doses: With longer treatment lasting up to 68 weeks, weight loss continued, particularly at higher doses: 12mg: average weight loss of up to 28.7% of body weight This longer-term data shows that weight loss with retatrutide can continue beyond one year, rather than plateauing early, especially at higher maintenance doses